Neurol. praxi. 2014;15(6):314-318

Migraine in women

MUDr. Zuzana Dean, MRCP
Neurologická klinika, FN, Nitra

Migraine is a predominantly female disorder. Menarche, menstruation, pregnancy, and menopause, and also the use of hormonal contraceptives and hormone replacement treatment may influence migraine occurrence. Migraine usually starts after menarche, occurs more frequently in the days just before or during menstruation, and ameliorates during pregnancy and menopause. Those variations are mediated by fluctuation of estrogen levels through their influence on cellular excitability. Moreover, administration of exogenous hormones may cause worsening of migraine and may expose migrainous women to an increased risk of vascular disease. Migraine with aura represents a risk factor for stroke. Administration of combined oral contraceptives to migraineurs may further increase the risk for ischemic stroke.

Keywords: migraine, estrogens, menstrual migraine, pregnancy, menopause, hormonal contraception

Published: December 20, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dean Z, MRCP. Migraine in women. Neurol. praxi. 2014;15(6):314-318.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amir B-Y, Yaacov B, Guy B, Gad P, Itzhak W, Gal I. Headaches in women undergoing in vitro fertilization and embryo-transfer treatment.Headache.2005; 45: 215-219. Go to original source... Go to PubMed...
    2. Benedetto C, Allais G, Ciochetto D, De Lorenzo C. Pathophysiological aspects of menstrual migraine. Cephalalgia. 1997; 17(suppl 2032-2034) Go to original source... Go to PubMed...
    3. Bousser MG, Conard J, Kittner S, De Lignieres B, MacGregor EA, Massiou H, Silberstein SD, Tzourio C. Recomendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The IHS Tak Force. Cephalagia, 2000; 20: 155-156. Go to original source... Go to PubMed...
    4. Bousser MG. Estrogens, Migraine and Stroke. Stroke, 2004. Go to original source...
    5. Brandes JL, The Influence of Estrogen on Migraine A Systematic Review, JAMA, April 19, 2006-Vol 295, No. 15. Go to original source... Go to PubMed...
    6. Evers, Áfra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force, European Journal of Neurology 2009; 16: 968-981. Go to original source... Go to PubMed...
    7. Facchinetti F, Sances G, Borella O, Genazzani AK, Nappi G. Magnesium Prophylaxis of Menstrual Migraine: Effects on Intracellular Magnesium, Headache: The Journal of Head and Face Pain Volume 31, Issue 5, pages 298-301, May 1991. Go to original source... Go to PubMed...
    8. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology 2012; 78: 1346-1353. Go to original source... Go to PubMed...
    9. Kurth T, Chabriat H, Bousser MG. Migraine and stroke: a complex association with clinical implications. The Lancet Neurology. Vol 11, 92-100, 2012. Go to original source... Go to PubMed...
    10. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: Thedepo-estradiol challenge test., Headache. 1996; 36: 367-371. Go to original source... Go to PubMed...
    11. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001; 41: 646-665. Go to original source... Go to PubMed...
    12. Mannix LS, Savani N, Landy S, Valade D, Shackelford S, Ames MH, Jones MW. Efficacy and Tolerability of Naratriptan for Short-Term Prevention of Menstrually Related Migraine: Data From Two Randomized, Double-Blind, Placebo-Controlled Studies Headache 2007; 47: 1037-1049). Go to original source... Go to PubMed...
    13. Olesen, et al. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 3rd edition. Cephalalgia. 2013 Jul; 33(9): 629-808. Go to original source...
    14. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases J Headache Pain. Apr 2012; 13(3): 177-189. Go to original source... Go to PubMed...
    15. Silberstein S MD, Hutchinson SL. Diagnosis and Treatment of the Menstrual Migraine Patient, Headache: The Journal of Head and Face Pain Volume 48, Issue Supplement s3, pages S115-S123, 2008. Go to original source... Go to PubMed...
    16. Silberstein S, Elkind AH, Schreiber C, Keywood Ch. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine Neurology July 27, 2004; 63(2): 261-269. Go to original source... Go to PubMed...
    17. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972; 22: 355-365. Go to original source... Go to PubMed...
    18. Somerville BW. The role of progesterone in menstrual migraine. Neurology. 1971; 21: 853-859. Go to original source... Go to PubMed...
    19. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarin S. Migraine Headache and Ischemic Stroke Risk: An Updated Meta-analysis, The Am J of Med 2010. Go to original source...
    20. Tzourio, Tehindrazanariveb A, Iglesias S, Alperovitch A, Chedru F, Angeljean-Chattilon J, Bausser MG. Case control study of migraine and risk of ischemic stroke in young women. BMJ. 1995; 310: 830-833. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.